|Bid||0.00 x 800|
|Ask||0.00 x 3000|
|Day's Range||11.79 - 12.20|
|52 Week Range||10.70 - 26.10|
|Beta (3Y Monthly)||0.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.50|
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Nancy Griffith, Ph.D., as vice president, scientific communications and medical operations, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Griffith will be responsible for the creation and implementation of AMAG’s medical communications and publication strategies.
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three years have been particularly tough on longer term AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shareholders. So t...
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
WALTHAM, Mass., April 02, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Ted Myles, chief financial officer, will present at the Needham 18th Annual.
March of Dimes and AMAG Pharmaceuticals, Inc. (AMAG) today announced Baystate Medical Center’s Wesson Women’s Clinic in Springfield, Mass. as the first Supportive Pregnancy Care (SPC) site, supported by AMAG to help improve mom and baby health during pregnancy, labor and delivery, and infancy.
For more than a decade, the recommended treatment for most pregnant women who previously had given birth prematurely was a weekly injection of a synthetic progestin hormone. On March 8, the company said a long-term clinical trial revealed no difference in the preterm birth rates of 1,700 pregnant women who took either their treatment, named Makena, or a placebo. Most experts and medical groups say it’s too early to make a call on Makena.
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In a 1,700-person clinical trial, about 11 percent of women who were administered the drug by Waltham-based Amag delivered their babies early, not significantly better than placebo participants.
Shares of AMAG Pharmaceuticals Inc. fell 6% after the company announced that its Phase 3 trial of Makena, a progestin therapy to reduce the risk of preterm birth, did not meet its primary endpoints. The trial, which enrolled 1700 patients, did not show a statistically significant difference between the treatment and placebo arms in preterm deliveries at less than 35 weeks. The trial also did not show a difference in neonatal morbidity and mortality, the company said. Makena is currently approved as a therapy to reduce the risk of preterm birth in women pregnant with a single baby who have a history of spontaneous single-baby preterm births. This latest trial was conducted as part of an approval commitment under the U.S. Food and Drug Administration's Subpart H accelerated approval process. The company said it would evaluate the data further, focusing on high-risk patients and patients enrolled in the U.S. The results could have been affected by the demographic makeup of the study's international cohort, which differed than the U.S.-based cohort of a previous trial that showed a difference in preterm births at 37 weeks, AMAG's Chief Medical Officer Julie Krop said. Shares of AMAG have fallen 22% in the past 3 months, and the S&P 500 has gained 4.4%.
AMAG Pharmaceuticals, Inc. (AMAG) announced today topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena® in patients with a history of a prior spontaneous singleton preterm delivery. The PROLONG trial was conducted as part of an approval commitment under the Food & Drug Administration’s (FDA) “Subpart H” accelerated approval process. The PROLONG trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints: the incidence of preterm delivery at less than 35 weeks (Makena treated group 11.0% vs. placebo 11.5%, p=.72) and the percentage of patients who met criteria for the pre-specified neonatal morbidity and mortality composite index (Makena treated group 5.4% vs 5.2%, p=.84).
AMAG Pharmaceuticals, Inc. (AMAG) announced today that new and encore data related to bremelanotide and Hypoactive Sexual Desire Disorder (HSDD) will be presented at the upcoming International Society for the Study of Women's Sexual Health (ISSWSH)/ International Society for Sexual Medicine (ISSM) Joint meeting taking place in Atlanta, Georgia on March 7-10. "AMAG’s significant presence at this year's ISSWSH/ISSM Joint Meeting underscores our deep commitment to raising awareness and understanding of HSDD, which is estimated to affect approximately one in ten premenopausal women in the United States,” said Julie Krop, M.D., chief medical officer and executive vice president of development at AMAG.
WALTHAM, Mass., March 05, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the following investor conferences during the.
AMAG Pharmaceuticals Inc is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and to aid in the diagnosis of cancer. Warning! GuruFocus has detected 4 Warning Signs with AMAG. For the last quarter AMAG Pharmaceuticals Inc reported a revenue of $88.1 million, compared with the revenue of $242.7 million during the same period a year ago.
WALTHAM, Mass., Feb. 19, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 38.78% and -2.17%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had a loss of 64 cents per share. Losses, adjusted to account for discontinued operations, were 60 cents per share. The results beat Wall Street expectations. ...
Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM,.
WALTHAM, Mass., Jan. 30, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2018 financial results will be released on.
AMAG Pharmaceuticals, Inc. (AMAG) announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio. Ciraparantag is in development as a single dose, ready-to-use solution for use in patients treated with novel oral anticoagulants (NOACs) or low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding.